The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Site Search
Showing 241 - 250 of 256 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
3 min read
News
|
|
3 min read
News
|
|
1 min read
News
|
|
1 min read
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.
News
|
|
3 min read
A transformative leader for more than two decades, Marshall will transition to advisory role
News
|
|
3 min read
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care.